Intensity Therapeutics (INTS) Stock: Buy, Sell, or Hold?
INTS - Intensity Therapeutics, Inc. Common stock
$3.44
0.23 (7.17%)
▲
5d:
-9.47%
30d:
-14.0%
90d:
-23.89%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When INTS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: INTS shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: INTS shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: INTS is currently trading at $3.44, which is considered oversold relative to its 30-day fair value range of $3.63 to $4.30.
Technical Outlook: Technically, INTS is in a downtrend. Immediate support is located at $3.21, while resistance sits at $4.30. The stock is showing strong short-term momentum, up 7.2% recently.
Market Sentiment: The stock scores a mixed 58/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $19.33 (+462.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, INTS is in a downtrend. Immediate support is located at $3.21, while resistance sits at $4.30. The stock is showing strong short-term momentum, up 7.2% recently.
Market Sentiment: The stock scores a mixed 58/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $19.33 (+462.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.63 -
$4.30
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
87.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (58/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+7.2%)
- BULLISH: Trading 462.0% below Wall St target ($19.33)
- WARNING: Composite score 50/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.63 -
$4.30
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.21
Resistance Level
$4.30
Current Trend
Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.73
Wall Street Target
$19.33
(+462.0%)
Share & Embed Analysis
Last updated: October 03, 2026 9:57 PM ET
Data refreshes hourly during market hours. Next update: 10:57 PM
Data refreshes hourly during market hours. Next update: 10:57 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INTS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$84 | 71 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$75 | 60 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$28 | 53 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 58 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$95 | 57 HOLD |
